Form4insider filings, from the source

SEC Form 4 · accession 0001209191-15-055578

SYNAGEVA BIOPHARMA CORP · GEVA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Period of report
Jun 22, 2015
Accepted (ET)
Jun 23, 2015 · 10:37 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000911326

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Options (Right to Buy)F1$10.10Jun 22, 2015D1,375D—Jul 21, 2019Common Stock1,3750D
Stock Options (Right to Buy)F2$11.35Jun 22, 2015D1,500D—Sep 22, 2020Common Stock1,5000D
Stock Options (Right to Buy)F3$20.60Jun 22, 2015D1,375D—Jun 26, 2018Common Stock1,3750D
Stock Options (Right to Buy)F4$23.00Jun 22, 2015D8,375D—Dec 20, 2021Common Stock8,3750D
Stock Options (Right to Buy)F5$23.95Jun 22, 2015D1,000D—Jun 27, 2017Common Stock1,0000D
Stock Options (Right to Buy)F6$40.32Jun 22, 2015D5,001D—Jun 6, 2023Common Stock5,0010D
Stock Options (Right to Buy)F7$40.74Jun 22, 2015D3,750D—Jun 27, 2022Common Stock3,7500D
Stock Options (Right to Buy)F8$80.35Jun 22, 2015D7,500D—Jun 4, 2024Common Stock7,5000D

Explanation of responses